China Kangtai Revenue Chart (OTCMKTS:CKGT)
$0.01 $0 (0%) CKGT stock closing price Jul 31, 2014 (Closing)
The latest 2011-Q3 China Kangtai revenue is 13.3M. Compare China Kangtai revenue chart with Yew Bio Pharm revenue, YIELD10 BIOSCI revenue.
China Kangtai Revenue Chart
You can do annual as well as quarterly comparisons of China Kangtai Cactus Bio-Tech Inc. net sales with its competitor companies like Yew Bio Pharm, YIELD10 BIOSCI. Over the 5 year period China Kangtai revenue in 2010 was highest at 36.02M. In the latest quarter, CKGT revenue 2011-Q3 has changed from 9.5M to 13.3M implying an increase of 40%.
China Kangtai Quarterly Revenue
* Past 5 years Range
|Max CKGT Revenue||$13.3M||Sep, 2011|
|Min CKGT Revenue||$2.76M||Mar, 2008|
China Kangtai Annual Revenue
* Past 5 years Range
|Max CKGT Revenue||$36.02M||Dec, 2010|
|Min CKGT Revenue||$14.24M||Dec, 2007|
China Kangtai Annual Revenue VS Peers
|China Kangtai Revenue||----||----||----||----||----||$36.02M||$26.53M||$20.3M||$14.24M|
|Yew Bio Pharm Revenue||$51.34M||$29.57M||$7.72M||$7.43M||$6.72M|
|YIELD10 BIOSCI Revenue||$1.15M||$2.59M||$2.8M||$5.39M||$42.31M|
|Yasheng Group Revenue||----||$938.89M||$1.01B||$1.01B||$993.1M|
China Kangtai Stock Articles
Revenue or net sales, also called topline or gross income is one of the most important financial metrics used to analyze a company. Revenue is the total amount of money that a company brings in through its various business activities, and appears as the ‘top line’ on the income statement. A company's net sales for a particular period can be found in its income statement. A healthy growth in revenue over time is generally considered good for the company, however other parameters such as profits must also be considered. We can calculate China Kangtai profits by subtracting expenses from China Kangtai revenue. Apart from analyzing a company's revenues over the years, it also helps to compare China Kangtai revenue with peers Yew Bio Pharm topline, Ricebran topline, China Ecological Agriculture Development topline; to see how the company is doing with respect to its peers.